HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Euthyroid Graves orbitopathy — Clinical Guidelines

Overview

Graves' orbitopathy (GO) affects 25-50% of patients with Graves' disease, characterized by inflammation and fibrosis around the eyes, leading to symptoms like proptosis, eyelid retraction, and diplopia. 1

Diagnosis

Clinical assessment for signs of proptosis, eyelid retraction, and ocular motility disturbances.

Use of clinical activity scores (CAS-7 and CAS-10) to grade disease activity.

Assessment of thyroid-related antibodies (TRAb) and IGF-1 levels to support diagnosis. 1

Management

First-line treatments: Glucocorticoids (e.g., intravenous methylprednisolone pulses) for active disease, with cumulative doses typically around 4.5 g. 5 7

Adjunctive therapies:

- Rituximab, tocilizumab, and teprotumumab show efficacy in refractory cases, with tocilizumab demonstrating significant reductions in clinical activity scores. 1 - IncobotulinumtoxinA (Xeomin) for managing upper eyelid retraction in inactive GO, with transconjunctival and transcutaneous applications showing comparable efficacy. 2

Referral: Moderate-to-severe cases should be referred to specialized centers for advanced management. 3

Special Populations

Comorbidities: Caution with glucocorticoid use in diabetic patients due to potential side effects; consider reducing steroid dose and opting for alternatives like orbital irradiation or surgical decompression if cushingoid features develop. 9

Safety considerations: High cumulative doses of intravenous glucocorticoids (>8 g) are associated with severe adverse events, including fatalities, highlighting the need for careful monitoring and dose management. 7

Key Recommendations

Initiate treatment with glucocorticoids, particularly intravenous methylprednisolone pulses with a cumulative dose of approximately 4.5 g, for active and severe Graves' orbitopathy. (Evidence: Strong 5 7)

Consider multidisciplinary management, combining endocrinology and ophthalmology, especially for complex cases to improve outcomes and patient care. (Evidence: Moderate 8)

Refer patients with moderate-to-severe GO promptly to specialized centers for advanced treatment options and surgical interventions when necessary. (Evidence: Moderate 3)

Use incobotulinumtoxinA for managing eyelid retraction in inactive GO, with either transconjunctival or transcutaneous application showing effective outcomes. (Evidence: Moderate 2)

Exercise caution with glucocorticoid dosing in diabetic patients and consider alternative treatments like orbital irradiation or surgery if significant side effects occur. (Evidence: Moderate 9)

References

1 Abumohssin AG, Alshareef RA, Aljohani S, Alqutub A, Alqutub A. Comparative efficacy and safety of rituximab, tocilizumab, and teprotumumab in Graves' orbitopathy: a systematic review and meta-analysis. Eye (London, England) 2025. link 2 Vokurka Topljak S, Galiot Delić M, Mandić K, Perić S, Baretić M, Juri Mandić J. Nonsurgical treatment for upper eyelid retraction in patients with inactive Graves' orbitopathy. International ophthalmology 2023. link 3 Perros P, Dayan CM, Dickinson AJ, Ezra D, Estcourt S, Foley P et al.. Management of patients with Graves' orbitopathy: initial assessment, management outside specialised centres and referral pathways. Clinical medicine (London, England) 2015. link 4 Perros P, Žarković M, Azzolini C, Ayvaz G, Baldeschi L, Bartalena L et al.. PREGO (presentation of Graves' orbitopathy) study: changes in referral patterns to European Group On Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012. The British journal of ophthalmology 2015. link 5 Riedl M, Kolbe E, Kampmann E, Krämer I, Kahaly GJ. Prospectively recorded and MedDRA-coded safety data of intravenous methylprednisolone therapy in Graves' orbitopathy. Journal of endocrinological investigation 2015. link 6 Hsu CH, Lin IC, Shen YD, Hsu WM. Ophthalmic plastic and orbital surgery in Taiwan. Journal of the Chinese Medical Association : JCMA 2014. link 7 Marcocci C, Watt T, Altea MA, Rasmussen AK, Feldt-Rasmussen U, Orgiazzi J et al.. Fatal and non-fatal adverse events of glucocorticoid therapy for Graves' orbitopathy: a questionnaire survey among members of the European Thyroid Association. European journal of endocrinology 2012. link 8 Wiersinga WM. Combined thyroid eye clinic: the importance of a multidisciplinary health care in patients with Graves' orbitopathy. Pediatric endocrinology reviews : PER 2010. link 9 Perros P, Baldeschi L, Boboridis K, Dickinson AJ, Hullo A, Kahaly GJ et al.. A questionnaire survey on the management of Graves' orbitopathy in Europe. European journal of endocrinology 2006. link

Euthyroid Graves orbitopathy